A Phase III Randomized Controlled Trial Comparing Dalpicilib-Enhanced Adjuvant Endocrine Therapy with Standard Adjuvant Endocrine Therapy in ER+ HER2- Lymph Node-Negative Early Breast Cancer with Risk Factors
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Dalpiciclib (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 18 Oct 2024 New trial record